Aromatase inhibitors clinical trials
A class of medicines: the studies that test any of its 11 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Aromatase Inhibitors.
Get an email when these change. Save the aromatase inhibitors studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
- Aminoglutethimide
- 2
- Trilostane
- 2
- Testolactone
- 2
- Ribociclib/Letrozole
- 1
- Liarozole
- 1
- 4-HYDROXYTESTOSTERONE
- 1
Studies by the year they started
604 studies that test it; most in 2008 (32)
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1996 | 5 |
| 1997 | 1 |
| 1998 | 8 |
| 1999 | 3 |
| 2000 | 12 |
| 2001 | 15 |
| 2002 | 14 |
| 2003 | 21 |
| 2004 | 28 |
| 2005 | 31 |
| 2006 | 24 |
| 2007 | 25 |
| 2008 | 32 |
| 2009 | 18 |
| 2010 | 16 |
| 2011 | 16 |
| 2012 | 19 |
| 2013 | 15 |
| 2014 | 16 |
| 2015 | 24 |
| 2016 | 29 |
| 2017 | 26 |
| 2018 | 25 |
| 2019 | 22 |
| 2020 | 27 |
| 2021 | 20 |
| 2022 | 27 |
| 2023 | 24 |
| 2024 | 20 |
| 2025 | 18 |
| 2026 | 22 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 117 · Other 491
Novartis Pharmaceuticals (25) · AstraZeneca (24) · Fudan University (13) · Pfizer (11) · M.D. Anderson Cancer Center (10) · Dana-Farber Cancer Institute (9) · Cairo University (8) · Assiut University (8)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 608
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Letrozole
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751Written as Letrozole
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953Written as Anastrazole
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06394804Written as Letrozole
- Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast CancerRecruitingPhase 2Medical College of WisconsinNCT06361940
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584Written as Anastrozole
- ALPINE: Maintenance Letrozole/AbemaciclibRecruitingPhase 2Dana-Farber Cancer InstituteNCT06366347Written as Letrozole
- A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before SurgeryRecruitingNot applicableMemorial Sloan Kettering Cancer CenterNCT06127979
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingPhase 3Celcuity IncNCT06757634Written as Arm C: Gedatolisib + Palbociclib + Letrozole
- De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast CancerNot yet recruitingPhase 2Montefiore Medical CenterNCT07866430Written as Letrozole
- Prescription of Letrozole for Uterine MyomaRecruitingPhase 4University of California, San FranciscoNCT06143631Written as Letrozole 2.5mg
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06979596Written as Letrozole
- Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingPhase 1Northwestern UniversityNCT07604272Written as Anastrozole (ARIMIDEX™)
- FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural CyclesRecruitingNot applicableUniversity of Novi SadNCT07425990Written as Letrozole (Aromatase Inhibitors)
- E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen StudyRecruitingPhase 1University of North Carolina, Chapel HillNCT07706374Written as Exemestane 25 MG
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07826052
- GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia PatientsRecruitingPhase 2/3Xiaojun ChenNCT05316935Written as Letrozole 2.5mg
- GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer PatientsRecruitingPhase 2/3Xiaojun ChenNCT06379113Written as Letrozole 2.5mg
- ETHAN - ET for Male BCRecruitingPhase 2Jose Pablo LeoneNCT05501704Written as Anastrozole
- Study of Letrozole in Recurrent GliomasRecruitingEarly Phase 1University of CincinnatiNCT03122197Written as Letrozole Oral Tablet
See all 608 studies that test one of the aromatase inhibitors →
Codes
What other systems call Aromatase inhibitors · ClinicalTrials.gg INT008849
- MeSH (NLM) D047072Aromatase InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D047072 | Aromatase Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.